Shandong: 115 drugs have been transferred out of medical insurance today!

Recently, Shandong Province Public Resource Exchange Center issued the "Notice on the province basic medical insurance, industrial injury insurance and maternity insurance drug list additions drugs in 2021 transferred out of work"
.
The notice pointed out that from November 1, 2021, 115 provincial supplementary drugs including aminobutyric acid, amrinone, benproperine, dezocine, BCG, etc.
will be transferred out of Shandong Province’s basic medical insurance and work-related injuries.
Insurance and maternity insurance drugs catalog, the cost of transferring drugs out of Shandong Province’s basic medical insurance, work injury insurance and maternity insurance funds will no longer be paid
.
In addition, starting from January 1, 2022, 339 drugs including cediadine will also be transferred out of the "Drug List
.
" Before the above-mentioned drugs are transferred out, continue to pay in accordance with the relevant provisions of the "Drug List"
.
It is understood that since this year, the transfer of local medical insurance has been very intensive
.
In addition to Shandong, Sichuan, Jiangsu, Beijing, Zhejiang and other places have also successively issued notices, clarifying that there will be a batch of drugs that will no longer be reimbursed this year
.
In this regard, the industry believes that according to the "14th Five-Year Plan for National Medical Insurance" previously issued by the state, it is clearly stated that it will continue to carry out the national unified medical insurance catalog in 2022 and dynamically adjust the medical insurance drug catalog.
More and more medicines will be expedited out of medical insurance within this period
.
On the whole, before July 1, 2020, September 1, 2020, October 1, 2020, January 1, 2021, July 1, 2021, and August 1, 2021, it was not The main time limit for the suspension of reimbursement of some local medical insurance products in less provinces
.
From recent related documents, a large number of drugs will be intensively transferred out of local medical insurance around January 1, 2022, including cerebroside-carnosine injections, cefoperazone tazobactam injections, oxiracetam injections, etc.
Some large varieties with sales exceeding one billion
.
However, what the country chooses to retreat is basically the drugs that have measured the efficacy, safety, drug price, sales and other factors
.
Therefore, the drugs that are withdrawn must have similar alternative drugs, and have more comprehensive advantages in terms of safety, economy, etc.
, which can better meet the needs of patients
.
It is worth mentioning that the industry predicts that during this process, the time interval for the adjustment of the medical insurance catalogue will continue to be shortened.
While the adjustment is more flexible, it may also accelerate the volume of innovative drugs, help them better seize the market, and improve new drugs at the same time.
Accessibility
.
However, it should be noted that although the products entering the medical insurance can be rapidly increased in a short period of time; however, as more and more drugs are brought out, it is also urgent to strive for new markets
.
In this regard, the industry has proposed that there are several options for related companies-one is not to reduce prices, and try to maintain sales at the hospital and expand out-of-hospital sales; the second is to actively reduce prices, try to maintain sales at the hospital and expand out-of-hospital sales; third, Look for opportunities to increase volume from the basic medicine catalog, Chinese medicine department, non-prescription drugs and other fields
.
Of course, in addition, pharmaceutical companies need to continue to increase their investment in innovation, by developing more innovative drugs and high-quality generic drugs, to enhance market competitiveness, and to prevent drugs from being transferred out of health insurance or causing intensified competition to affect their own performance.
Shock
.